CYTK today
$57.56-$0.97 (-1.65%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bullish
1 hourExpanding
15 minStrong Bullish
5 minLeaning Bullish
Daily trend turns up above $65.57
Key levels
Resistance$64.50
Resistance$60.15
Support$53.55
Support$50.15
Latest news & SEC filings
LegalCytokinetics requests FDA label update for Myqorzo
ProductCytokinetics shares additional aficamten findings at HCMS meeting
ProductCytokinetics reports aficamten study results at HCMS 2026 sessions
All CYTK news →About Cytokinetics
Cytokinetics is a biopharmaceutical company that discovers, develops, and commercializes medicines targeting muscle function. Its approved product, MYQORZO (aficamten), is a cardiac myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy, sold in the U.S. and Europe, with Sanofi handling China and Bayer handling Japan. The company also runs clinical programs for other cardiac and skeletal muscle conditions, including omecamtiv mecarbil, ulacamten, and CK-089.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
CYTOKINETICS INC (CYTK)
What Is the Price Target for CYTK?
SEPT Low Target
$100.00
SEPT Mid Target
$112.00
SEPT High Target
$140.00
Analyst Consensus
$112.00
Is CYTK a Buy or Sell Right Now?
Thesis
- •Revenue growing 376.6% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for CYTK.
Start Free Trial →Is CYTK Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$112.00
32
Moat Score
NONE
2/9
Piotroski Score
-4.2
Altman Z-Score
What Is Smart Money Doing with CYTK?
Insider Signal
SELLING
0 buys / 8 sells (90d)
Congress Signal
BUYING
4 buys / 1 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Malik Fady Ibraham | officer | Buy | 3,500 | $27K | Nov 3, 2026 |
| Malik Fady Ibraham | officer | Sale | 3,500 | $220K | Nov 3, 2026 |
| Malik Fady Ibraham | officer | Buy | 3,500 | $27K | Oct 20, 2026 |
| Malik Fady Ibraham | officer | Sale | 3,500 | $224K | Oct 20, 2026 |
| Wysenski Nancy | director | Buy | 97 | $6K | Oct 16, 2026 |
| Kaye Edward M. MD | director | Buy | 195 | $12K | Oct 16, 2026 |
| Harrington Robert Arthur | director | Buy | 195 | $12K | Oct 16, 2026 |
| Daly James M | director | Buy | 195 | $12K | Oct 16, 2026 |
| WIERENGA WENDELL | director | Buy | 97 | $6K | Oct 16, 2026 |
| HENDERSON JOHN T | director | Buy | 352 | $22K | Oct 16, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →CYTK Growth Story
Revenue YoY
376.6%
3yr Revenue CAGR
-2.4%
EPS Growth YoY
-24.33%
FCF Growth YoY
-33.8%
Revenue Trend
ACCELERATING
Dark Pool Trades for CYTK
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for CYTK, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 14:57:36 | $57.28 | 1,818 | $$104K | SELL |
| 14:54:25 | $57.56 | 1,529 | $$88K | SELL |
| 14:47:25 | $57.45 | 1,000 | $$57K | SELL |
| 21:00:30 | $58.53 | 1,358 | $$79K | BUY |
| 21:00:28 | $58.53 | 2,032 | $$119K | BUY |
5 dark pool trades shown · $$448K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for CYTK
PREVIEWSEPT Investing provides real-time options flow tracking for CYTK, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $57.5 | Nov 20 | 8 | $$290 | 1 | SWEEP |
| CALL | $70 | Nov 20 | 8 | $$275 | 11 | SWEEP |
2 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
What Traders Are Saying About CYTK
3 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for CYTK. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Zone Setup — $CYTK (CYTOKINETICS INC) Price: $63.31 | Zone: $59.78 — $66.92 Conviction: HIGH | Analyst upside: +77.8% Middle of range (49% of range) — no edge yet. Strong positive news (3+ vs 0-). A...
SEPT Brain on $CYTK -- Neutral CYTK at $69.05. Uptrend holds while above $67.92. $75 psychological level is the next resistance to watch. The Play: Watch for a decisive move from current levels with...
SEPT Brain on $CYTK -- Neutral Bounced back with 100% buying after prior session selling. Uptrend holds while above $72.15. $100 psychological level is the next resistance to watch. The Play: Three ...
Join 3,500+ traders discussing CYTK in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for CYTOKINETICS INC (CYTK) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →CYTK — frequently asked questions
What is CYTK stock price today?
CYTOKINETICS INC (CYTK) is at $57.56, down 1.65% (-$0.97) at the Nov 12, 2026 close.
Why is CYTK stock moving today?
Latest CYTK news — Nov 9, 2026: Cytokinetics requests FDA label update for Myqorzo · Nov 9, 2026: Cytokinetics shares additional aficamten findings at HCMS meeting
Why did CYTK stock move on Nov 9, 2026?
Cytokinetics shares closed at $55.14, up 1.40% on volume of about 3.06 million shares, as the company pursued a regulatory catalyst by requesting an FDA label update for its drug Myqorzo, a move that could change how and for whom the medicine is cleared to be used. The stock also drew attention from additional clinical updates, with Cytokinetics presenting further aficamten findings and reporting results from its ACACIA-HCM and FOREST-HCM trials at the HCMS Scientific Sessions 2026.
What is the CYTK price target?
The average analyst price target for CYTK is $112.00, ranging from $100 to $140, based on 15 analysts. Latest: Leerink Partners maintains on Nov 5, 2026.
What do analysts rate CYTK?
Analyst ratings for CYTK: 19 Buy, 2 Hold, 0 Sell — consensus Buy.
Did CYTK beat earnings?
CYTK last reported on Nov 4, 2026: EPS -$1.37 vs -$1.44 expected — a beat of 4.9%.
Does CYTK pay a dividend?
CYTK does not currently pay a dividend.
What are CYTK support and resistance levels?
Support: $53.55, $50.15, $47.34. Resistance: $60.15, $64.50, $67.27.
What are insiders doing with CYTK?
Insider activity: SELLING, 0 buys and 8 sells in the last 90 days.
What is the latest news on CYTK?
Nov 9, 2026: Cytokinetics requests FDA label update for Myqorzo · Nov 9, 2026: Cytokinetics shares additional aficamten findings at HCMS meeting · Nov 9, 2026: Cytokinetics reports aficamten study results at HCMS 2026 sessions